NeOnc Technologies (NTHI)
Develops intranasal NEO100 and oral NEO212 candidates for brain tumors.
Something off on this page? Send us feedback.
Develops intranasal and oral bio-conjugated candidates for malignant brain tumors and other central nervous system cancers, centered on NEO100 and NEO212. The pre-commercial biotechnology business is financed mainly through equity, loans, and prospective partnerships, and depends on a USC license and contract manufacturers.
Develops intranasal and bio-conjugated drug-delivery candidates for malignant brain tumors and other central nervous system cancers. NEO100 uses highly purified perillyl alcohol administered intranasally; NEO212 joins perillyl alcohol with temozolomide in an oral molecule. Neither candidate is approved for marketing.
Operates from California around a USC-origin clinical and intellectual-property relationship, while adding UAE clinical-research pathways through NuroMENA. The business runs as a single biotechnology segment, with research and development financed primarily by equity sales, bridge loans, and prospective partnerships rather than commercial product sales.
Relies on an exclusive, royalty-bearing USC license for the core platform and on third-party manufacturers for clinical raw materials, active ingredients, and finished products. Five full-time employees support the internal operating base.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $2.0M · Total debt $328.2K · Total assets $5.2M · Shareholders' equity −$18.5M
- Revenue
- $0
- Operating income
- −$14.1M
- Net income
- −$14.2M
No dividends on record.
| Institutions22 holders · as of Jun 30, 2026 | 16.21% | 3.16M shares | |
| Insiders8 holders · as of Nov 24, 2025 | 47.29% | 9.21M shares | |
| Otherremainder | 36.50% | 7.11M shares |
19.47M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (19.47M in the company's Sep 3, 2026 report, 25.93M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Amir F. Heshmatpour1Insiderdirector, 10 percent owner, officer: President | 33.40% | 6.49M | 13Dfiled Nov 24, 2025 ↗ |
Cinctive Capital Management LPInstitution | 8.25% | 1.61M | 13Fas of Jun 30, 2026 |
Ming-Fu (alan) ChiangInsiderdirector | 6.62% | 1.29M | Form 4filed Nov 24, 2025 ↗ |
Thomas C. ChenInsiderdirector, 10 percent owner, officer: CEO | 4.17% | 812,910 | Form 4filed May 23, 2025 ↗ |
Vanguard Capital Management LLCInstitution | 2.59% | 504,171 | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
- Amir F. Heshmatpour's transaction reports restate only vehicles that traded; the 2025 ownership statement (6.49M) plus the 16.5K net shares acquired since is used instead.
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Nov 20, 2025 | Yousha Neman-Ebrahim | officer: Chief Clinical Officer | +1,100 | $6.69 |
| Nov 21, 2025 | Amir F. Heshmatpour | director, 10 percent owner, officer: President | +24,000 | $6.07 |
| Nov 24, 2025 | Amir F. Heshmatpour | director, 10 percent owner, officer: President | +6,000 | $6.51 |
- Novocure
Marketed Tumor Treating Fields in newly diagnosed and recurrent GBM.
- Kazia Therapeutics (ADR)
Brain-penetrant GBM and IDH-mutant-glioma clinical pipeline rival.
- Inovio Pharmaceuticals
Phase 2 DNA-immunotherapy program in newly diagnosed GBM.
- Cerenome
Phase 2 recurrent-GBM radiotherapy plus pediatric-CNS programs.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| NeOnc Technologies | $4.96 | +4.86% | $128.6M | — | — | — | — |
| Novocure | $18.30 | +2.61% | $2.08B | — | — | 3.0 | +15.6% |
| Kazia Therapeutics (ADR) | $13.35 | +4.87% | $20.4M | — | — | 1,444.7 | — |
| Inovio Pharmaceuticals | $1.33 | −2.21% | $94.0M | — | — | — | — |
| Cerenome | $2.76 | −4.50% | $20.2M | — | — | 4.8 | — |
| Median | — | — | 4.8 | +15.6% |